KR20140026783A - Organic light-emitting compound and organic electroluminescent device using the same - Google Patents
Organic light-emitting compound and organic electroluminescent device using the same Download PDFInfo
- Publication number
- KR20140026783A KR20140026783A KR1020120092403A KR20120092403A KR20140026783A KR 20140026783 A KR20140026783 A KR 20140026783A KR 1020120092403 A KR1020120092403 A KR 1020120092403A KR 20120092403 A KR20120092403 A KR 20120092403A KR 20140026783 A KR20140026783 A KR 20140026783A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- unsubstituted
- substituted
- condensed
- synthesis
- Prior art date
Links
Classifications
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/14—Carrier transporting layers
- H10K50/16—Electron transporting layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/14—Carrier transporting layers
- H10K50/15—Hole transporting layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/60—Organic compounds having low molecular weight
- H10K85/631—Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine
- H10K85/633—Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine comprising polycyclic condensed aromatic hydrocarbons as substituents on the nitrogen atom
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/60—Organic compounds having low molecular weight
- H10K85/649—Aromatic compounds comprising a hetero atom
Landscapes
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Electroluminescent Light Sources (AREA)
Abstract
Description
본 발명은 신규의 유기발광 화합물 및 이를 이용한 유기 전계 발광 소자에 관한 것으로, 보다 상세하게는 발광능, 정공 수송능, 전자 수송능 등이 우수한 신규의 유기발광 화합물 및 이를 하나 이상의 유기물층에 포함함으로써 발광효율, 구동 전압, 수명 등의 특성이 향상된 유기 전계 발광 소자에 관한 것이다.
The present invention relates to a novel organic light emitting compound and an organic electroluminescent device using the same. More particularly, the present invention relates to a novel organic light emitting compound having excellent light emitting ability, hole transporting ability, and electron transporting ability, An organic electroluminescent device having improved characteristics such as efficiency, driving voltage, and lifetime.
유기 전계 발광 소자(organic electroluminescent device) (이하, 유기 EL 소자라 함)는 통상 양극과 음극 및 이들 사이에 유기물층을 포함하는 구조를 가진다. 여기서 유기물층은 유기 EL 소자의 효율과 안정성을 높이기 위하여 각기 다른 물질로 구성된 다층의 구조로 이루어진 경우가 많으며, 예컨대 정공 주입층(HIL), 정공 수송층(HTL), 발광층(EML), 전자 수송층(ETL), 전자 주입층(EIL) 등을 포함할 수 있다. An organic electroluminescent device (hereinafter referred to as an organic EL device) generally has a structure including an anode, a cathode, and an organic material layer therebetween. In this case, the organic material layer is often composed of a multilayer structure composed of different materials in order to increase the efficiency and stability of the organic EL device, for example, a hole injection layer (HIL), a hole transport layer (HTL), a light emitting layer (EML), an electron transport layer (ETL) ), An electron injection layer (EIL), and the like.
이러한 유기 EL 소자의 두 전극 사이에 전압을 걸어주게 되면 양극에서는 정공이, 음극에서는 전자가 유기물층으로 주입되고, 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다.When a voltage is applied between the two electrodes of the organic EL device, holes are injected into the anode, electrons are injected into the organic layer, and excitons are formed when injected holes and electrons meet. When falling, the light comes out.
유기 EL 소자의 발광층 형성재료는 발광색에 따라 청색, 녹색, 적색 발광 재료로 구분될 수 있다. 그밖에, 보다 나은 천연색을 구현하기 위한 발광재료로 노란색 및 주황색 발광재료도 사용된다. 또한, 색순도의 증가와 에너지 전이를 통해 발광 효율을 증가시키기 위하여, 발광 재료로서 호스트/도펀트 계를 사용할 수 있다. 그 원리는 발광층을 주로 구성하는 호스트보다 에너지 대역 간극이 작고 발광 효율이 우수한 도펀트를 발광층에 소량 혼합하면, 호스트에서 발생한 엑시톤이 도펀트로 수송되어 효율이 높은 빛을 내는 것이다. 이때 호스트의 파장이 도펀트의 파장대로 이동하므로, 이용하는 도판트의 종류에 따라 원하는 파장의 빛을 얻을 수 있다. The light emitting layer forming material of the organic EL device can be classified into blue, green and red light emitting materials depending on the luminescent color. In addition, yellow and orange light emitting materials are also used as light emitting materials for realizing better color. In addition, in order to increase luminous efficiency through increasing color purity and energy transfer, a host / dopant system may be used as the light emitting material. The principle is that when a small amount of dopant having a smaller energy band gap and higher luminous efficiency than a host mainly constituting the light emitting layer is mixed with a light emitting layer in a small amount, the excitons generated in the host are transported as a dopant to emit light with high efficiency. At this time, since the wavelength of the host is shifted to the wavelength of the dopant, light having a desired wavelength can be obtained according to the type of dopant to be used.
일반적으로 인광 호스트 재료로는 CBP(4,4-dicarbazolybiphenyl) 등의 카바졸계 화합물 등이 사용되며, 인광 도판트 재료로는 Ir, Pt 등의 중원자(heavy atoms)가 포함된 금속 착체 화합물이 널리 사용되고 있다. In general, a phosphorescent host material is a carbazole-based compound such as 4,4-dicarbazolylbiphenyl (CBP), and a phosphorescent dopant is a metal complex compound containing heavy atoms such as Ir and Pt .
그러나 현재 사용되는 인광 호스트 재료인 CBP의 경우 유리전이온도(Tg)가 110℃ 정도로 낮으며, 소자 내의 결정화가 쉽게 일어나 유기 EL 소자의 수명이 150 시간 정도로 매우 짧은 문제점이 있다.
However, CBP, which is a phosphorescent host material currently used, has a low glass transition temperature (T g ) of about 110 ° C. and easily crystallizes in the device, resulting in a very short lifetime of the organic EL device to about 150 hours.
본 발명은 상기한 문제점을 해결하기 위해 안출된 것으로서, 발광효율, 구동전압, 열적 안정성, 수명 등의 특성을 향상시킬 수 있는 유기발광 화합물 및 이를 이용한 유기 EL 소자를 제공하는 것을 목적으로 한다.
SUMMARY OF THE INVENTION The present invention has been devised to solve the problems described above, and it is an object of the present invention to provide an organic light emitting compound and an organic EL device using the same, which can improve characteristics such as luminous efficiency, driving voltage, thermal stability and lifetime.
상기 목적을 달성하기 위하여 본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다. In order to achieve the above object, the present invention provides a compound represented by the following general formula (1).
상기 식에서,Where
X 및 Y는 서로 같거나 또는 상이하며, 각각 독립적으로 N 또는 CH이고;X and Y are the same or different and are each independently N or CH;
R1 및 R2은 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, -NR3R4, 치환 또는 비치환된 C3~C40의 시클로알킬기, 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며, R 1 and R 2 are the same or different and each independently represents a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 ~ C 40 of the alkynyl group, a substituted or unsubstituted C 6 ~ C 40 aryl group, a substituted or unsubstituted nuclear atoms of 5 to 40 heteroaryl group, a substituted or unsubstituted C 6 ~ aryloxy of C 40 A substituted or unsubstituted C 1 to C 40 alkyloxy group, -NR 3 R 4 , a substituted or unsubstituted C 3 to C 40 cycloalkyl group, and a substituted or unsubstituted 3 to 40 Or a group which forms a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring with a group adjacent to the condensed aliphatic ring, condensed aromatic ring, condensed heteroaromatic ring or condensed heteroaromatic ring,
여기서 R3 및 R4는 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C3~C40의 시클로알킬기 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며, Wherein R 3 and R 4 are the same or different and each independently represents a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted nucleus A heteroaryl group having 5 to 40 atoms, a substituted or unsubstituted C 3 to C 40 cycloalkyl group, and a substituted or unsubstituted heterocycloalkyl group having 3 to 40 nucleus atoms, or a group selected from the group consisting of A condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring,
R5는 H, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, -NRaRb, 치환 또는 비치환된 C3~C40의 시클로알킬기 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며, R 5 is H, a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group, a C 6 ~ C 40 aryl group, a substituted or unsubstituted nuclear atoms heteroaryl of 5 to 40, a substituted or unsubstituted C 6 ~ C 40 of the aryloxy group, a substituted or unsubstituted C 1 ~ C 40 alkyloxy of, -NR a R b, a substituted or unsubstituted selected from the group consisting of a cycloalkyl group of C 3 ~ C 40 unsubstituted and substituted or unsubstituted heteroaryl number of 3 to 40 nuclear atoms or a cycloalkyl group, or they A group forming a condensed aliphatic ring, a condensed aromatic ring, a condensed hetero aliphatic ring or a condensed heteroaromatic ring,
여기서 Ra, Rb는 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기 및 치환 또는 비치환된 C3~C40의 시클로알킬기로 이루어진 군에서 선택되며, 또는 이들이 인접하는 기들은 서로 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성할 수 있다.Wherein R a and R b are the same or different and each independently represents a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C of 2 ~ C 40 alkynyl group, a substituted or unsubstituted C 6 ~ C 40 aryl group, a substituted or unsubstituted nuclear atoms of 5 to 40 heteroaryl group, a substituted or unsubstituted in the ring C 6 ~ C 40 aryl A substituted or unsubstituted C 1 to C 40 alkyloxy group and a substituted or unsubstituted C 3 to C 40 cycloalkyl group, or groups adjacent thereto may be bonded to each other to form a condensed aliphatic ring , Condensed aromatic rings, condensed heteroaliphatic rings or condensed heteroaromatic rings.
본 발명은 또한 (i) 양극, (ⅱ) 음극, 및 (ⅲ) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 EL 소자로서, 상기 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함하는 것을 특징으로 하는 유기 EL 소자를 제공한다. The present invention also provides an organic EL device comprising (i) an anode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode, And a compound represented by the following general formula (1): < EMI ID = 1.0 >
이때, 상기 화학식 1로 표시되는 화합물을 포함하는 유기물층은 정공 주입층, 정공 수송층 및 발광층으로 이루어진 군에서 선택될 수 있으며, 구체적으로 상기 화학식 1로 표시되는 화합물은 발광층의 인광 호스트로 사용될 수 있다.
In this case, the organic compound layer including the compound represented by Formula 1 may be selected from the group consisting of a hole injection layer, a hole transport layer, and a light emitting layer. Specifically, the compound represented by Formula 1 may be used as a phosphorescent host of a light emitting layer.
본 발명의 화학식 1로 표시되는 화합물은 우수한 발광능, 전자 수송능 및 정공 수송능을 가지고 있다. 따라서, 이를 포함하는 유기 EL 소자는 발광성능, 구동전압, 수명 등의 특성이 크게 향상될 수 있으므로, 풀 칼라 디스플레이 패널 등에 효과적으로 적용될 수 있다.
The compound represented by the formula (1) of the present invention has excellent luminous ability, electron transport ability and hole transport ability. Therefore, the organic EL device including the same may greatly improve characteristics such as light emission performance, driving voltage, and lifetime, and thus may be effectively applied to a full color display panel.
이하, 본 발명에 대하여 상세히 설명한다. Hereinafter, the present invention will be described in detail.
<신규 화합물><Novel compound>
본 발명에 따른 신규 유기발광 화합물은 퀴나졸린(Quinazoline)계의 모핵에 다양한 치환체, 특히 N-함유 헤테로환, 방향족 고리 등이 연결된 상기 화학식 1로 표시되는 구조를 가진다. 이러한 구조를 통해 충분히 높은 삼중항 에너지 레벨을 달성하여 인광특성을 개선함과 동시에 전자(electron) 및/또는 정공(hole) 수송 능력, 발광효율, 구동전압, 수명 특성 등에서 개선된 효능을 달성할 수 있다.The novel organic electroluminescent compound according to the present invention has a structure represented by the above formula (1) in which various substituents, particularly N-containing heterocyclic rings, aromatic rings, and the like, are connected to the parent moiety of the quinazoline system. Through such a structure, it is possible to attain a sufficiently high triplet energy level to improve the phosphorescence characteristic and at the same time to achieve an improved effect in electron and / or hole transporting ability, luminous efficiency, driving voltage, have.
본 발명에 따라 화학식 1로 표시되는 화합물에서, 상기 X 및 Y는 서로 같거나 또는 상이하며, 각각 독립적으로 N 또는 CH이다. 일례로, Y가 N이고 X가 CH이거나 Y가 CH이고 X가 N일 수 있다. 또한 X 및 Y 모두가 CH이거나, 또는 N 일 수도 있다. In the compound represented by the formula (1) according to the present invention, X and Y are the same or different and each independently N or CH. In one example, Y is N, X is CH, or Y is CH and X is N. Also, both X and Y may be CH or N. [
상기 화학식 1에서, R1 및 R2은 서로 같거나 또는 상이하며, 각각 독립적으로 C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, -NR3R4, C3~C40의 시클로알킬기 및 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나; 또는 이들이 인접하는 기와 서로 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기일 수 있다. Wherein R 1 and R 2 are the same or different and each independently represents a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 6 to C 40 alkynyl group, for C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of the aryloxy group, C 1 ~ C 40 alkyloxy group of, -NR 3 R 4, C of 3 ~ C 40 cycloalkyl An alkyl group and a heterocycloalkyl group having 3 to 40 nuclear atoms; Or a group which forms a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring by bonding with the adjacent groups.
여기서, R3 및 R4는 서로 같거나 또는 상이하며, 각각 독립적으로 C1~C40의 알킬기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C3~C40의 시클로알킬기 및 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나; 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이다.Wherein R 3 and R 4 are the same or different and each independently represents a C 1 to C 40 alkyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 3 to C selected from the group consisting of cycloalkyl group and 40 nuclear atoms, 3 to 40 or a heterocycloalkyl group of; Or a group in which they form a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring, or a condensed heteroaromatic ring adjacent to each other.
R5는 서로 같거나 또는 상이하며, 각각 독립적으로 H, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, -NRaRb, C3~C40의 시클로알킬기 및 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 서로 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이다. R 5 are the same or different and each independently represents H, a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, A heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group, -NR a R b , a C 3 to C 40 cycloalkyl group, Or a heterocycloalkyl group having 1 to 40 carbon atoms, or a group in which they are bonded to each other to form a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring, or a condensed heteroaromatic ring.
여기서 Ra, Rb는 서로 같거나 또는 상이하며, 각각 독립적으로 C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C3~C40의 시클로알킬기, 및 C3~C40의 헤테로시클로알킬기로 이루어진 군에서 선택되며, 또는 이들이 인접하는 기들과 서로 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성할 수 있다.Wherein R a and R b are the same or different and each independently represents a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 6 to C 40 aryl , A heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group, a C 3 to C 40 cycloalkyl group, and a C 3 to C 40 hetero A cycloalkyl group, or they may be bonded to each other to form a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring.
한편 본원 화학식 1에서, '치환 또는 비치환된' 이라는 용어가 기재된 치환기인 R1~R5, Ra, Rb, 보다 구체적으로 상기 R1~R5, Ra, Rb 에서, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C3~C40의 시클로알킬기 및 핵원자수 3 내지 40의 헤테로시클로알킬기는, 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C6~C40의 아릴알킬기, C3~C40의 시클로알킬기, C3~C40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되는 하나 이상의 치환기로 치환될 수 있다.Meanwhile, in the present formula I, in which R 1 ~ substituent, the term "substituted or unsubstituted" described R 5, R a, R b, more specifically, the R 1 ~ R 5, R a, R b, C 1 a ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of the aryloxy group, C 1 ~ C 40 alkyloxy group of, C 3 ~ C cycloalkyl group and nuclear atoms, 3 to heterocycloalkyl group of 40 of the 40 are each independently selected from deuterium, halogen, cyano group, C 1 ~ C 40 the alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, an aryloxy group of a heteroaryl group of C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40, C 6 ~ C 40 of the , A C 1 to C 40 alkyloxy group, a C 6 to C 40 arylamine group, a C 6 to C 40 arylalkyl group, a C 3 to C 40 cycloalkyl group, a C 3 to C 40 heterocycloalkyl group, a C 1 ~ C 40 alkylsilyl group, and C 6 ~ C 40 aryl group consisting of silyl Or a salt thereof may be substituted.
본 발명에 따른 화학식 1로 표기되는 화합물에서, 삼중항 에너지 레벨을 고려했을 때, 상기 R1 및 R2은 서로 같거나 또는 상이하며, 각각 독립적으로 C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, -NR3R4이거나, 또는 이들 작용기가 인접한 기와 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기인 것이 바람직하다. 이때 R1 및 R2는 각각 C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기 또는 NR3R4인 경우가 더욱 바람직하고, NR3R4인 경우가 가장 바람직하다.In the compound represented by the formula (1) according to the present invention, when considering the triplet energy level, R 1 and R 2 are the same or different and each independently represents a C 6 to C 40 aryl group, A heteroaryl group having 5 to 40 carbon atoms, -NR 3 R 4 , or a group which forms a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring by bonding these adjacent groups to adjacent groups. Wherein R 1 and R 2 are most preferably in the case where the more preferable, and NR 3 R 4 when the respective C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, or an NR 3 of R 4.
여기서, 상기 C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, R3, R4는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C6~C40의 아릴알킬기, C3~C40의 시클로알킬기, C3~C40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되는 하나 이상의 치환기로 치환될 수 있다. Here, the C 6 ~ C 40 aryl group, nuclear atoms aryl of from 5 to 40 heteroaryl group, R 3, R 4 are each independently a heavy hydrogen, a halogen, cyano group, C 1 ~ C 40 alkyl group, C 2 ~ of aryloxy C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of, C 1 ~ C 40 A C 6 to C 40 arylamine group, a C 6 to C 40 arylalkyl group, a C 3 to C 40 cycloalkyl group, a C 3 to C 40 heterocycloalkyl group, a C 1 to C 40 alkyl A silyl group, and an arylsilyl group of C 6 to C 40 may be substituted with at least one substituent selected from the group consisting of
일례로, 상기 C6~C40의 아릴기 또는 핵원자수 5 내지 40의 헤테로아릴기는 페닐, 나프틸, 인덴, 안트라센, 페난트렌, 파이렌, 트리페닐렌, 피리딘, 피리미딘, 피라진, 트리아진, 퀴놀린, 이소퀴놀린, 퀴녹살린, 플루오렌, 카바졸, 디벤조싸이오펜, 디벤조퓨란, 아크리딘, 인돌, 벤조퓨란, 벤조싸이오펜, 벤즈이미다졸, 벤조싸이아졸, 퓨린, 페난트롤린일 수 있다. For example, the C 6 -C 40 aryl group or the heteroaryl group having 5 to 40 nuclear atoms may be substituted with at least one group selected from phenyl, naphthyl, indene, anthracene, phenanthrene, pyrene, triphenylene, pyridine, pyrimidine, pyrazine, And examples thereof include azine, quinoline, isoquinoline, quinoxaline, fluorene, carbazole, dibenzothiophene, dibenzofuran, acridine, indole, benzofuran, benzothiophene, benzimidazole, benzothiazole, It can be Lin.
본 발명에 따른 상기 화학식 1의 화합물은 하기 화학식 2 내지 화학식 4로 표시되는 화합물 중의 어느 하나로 보다 구체화될 수 있다.The compound of formula (1) according to the present invention may be further compounded by any one of the compounds represented by the following formulas (2) to (4).
상기 식에서, Where
R1는 C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기 또는 NR3R4이고;R 1 is a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms or NR 3 R 4 ;
R2, R3 및 R4는 앞서 정의된 바와 같다.R 2 , R 3 and R 4 are as defined above.
이때 R2는C6~C40의 아릴기 또는 핵원자수 5 내지 40의 헤테로아릴기인 것이 바람직하다. R 2 is preferably a C 6 to C 40 aryl group or a heteroaryl group having 5 to 40 nuclear atoms.
본 발명에서 사용된 "비치환된 알킬"은 탄소수 1 내지 40(10)의 직쇄 또는 측쇄의 포화 탄화수소이며, 이의 예로는 메틸, 에틸, 프로필, 이소부틸, sec-부틸, 펜틸, iso-아밀, 헥실 등을 포함한다.As used herein, “unsubstituted alkyl” is a straight or branched chain saturated hydrocarbon of 1 to 40 (10) carbon atoms, examples of which are methyl, ethyl, propyl, isobutyl, sec-butyl, pentyl, iso-amyl, Hexyl and the like.
"비치환된 아릴"은 단독 고리 혹은 2 이상의 고리가 조합된, 탄소수 6 내지 40(8)의 방향족 부위를 의미한다. 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태로 부착될 수 있다."Unsubstituted aryl" means an aromatic moiety having 6 to 40 (8) carbon atoms, singly or in combination of two or more rings. Two or more rings may be attached to each other in a pendant or condensed form.
"비치환된 헤테로아릴"은 핵원자수 5 내지 40(8)의 모노헤테로사이클릭 또는 폴리헤테로사이클릭 방향족 부위를 의미하며, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S와 같은 헤테로원자로 치환된다. 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태로 부착될 수 있고, 나아가 지방족 고리 또는 방향족 고리와의 축합된 형태도 포함하는 것으로 해석한다."Unsubstituted heteroaryl" means a monoheterocyclic or polyheterocyclic aromatic moiety having 5 to 40 (8) nucleoatoms, wherein at least one carbon in the ring, preferably 1 to 3 carbons is N, Substituted by heteroatoms such as O and S. Two or more rings may be attached in a pendant or condensed form to each other and further include a condensed form with an aliphatic ring or an aromatic ring.
"축합 고리"는 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리, 축합 헤테로방향족 고리 또는 이들의 조합된 형태를 의미한다."Condensation ring" means a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring, a condensed heteroaromatic ring, or a combination thereof.
이상에서 설명한 본 발명의 화학식 1로 표시되는 화합물은 하기 예시된 화학식들로 보다 구체화될 수 있다. 그러나 본 발명의 화학식 1로 표시되는 화합물이 하기 예시된 것들에 의해 한정되는 것은 아니다. The compound represented by the formula (1) of the present invention described above may be further embodied by the formulas illustrated below. However, the compounds represented by formula (1) of the present invention are not limited by the following examples.
일례로, 본원 화학식 2로 표시되는 화합물은 하기 예시된 화합물 1-1 내지 1-20으로 보다 구체화될 수 있으며, 상기 화학식 3으로 표시되는 화합물은 하기 예시된 화합물 2-1 내지 2-20으로 보다 구체화될 수 있다. 또한 상기 화학식 4로 표시되는 화합물은 하기 예시된 화합물 3-1 내지 3-20으로 보다 구체화될 수 있다. For example, the compound represented by the general formula (2) may be further exemplified by the following exemplified compounds 1-1 to 1-20, and the compound represented by the general formula (3) may be exemplified by the following exemplified compounds 2-1 to 2-20 Can be embodied. Further, the compound represented by the above formula (4) can be further compounded by the following exemplified compounds 3-1 to 3-20.
본 발명의 화학식 1의 화합물은 일반적인 합성방법에 따라 합성될 수 있다. 본 발명의 화합물에 대한 상세한 합성 과정은 후술하는 합성예에서 구체적으로 기술하도록 한다.
The compound of formula 1 of the present invention may be synthesized according to a general synthetic method. Detailed synthesis of the compound of the present invention will be described in detail in Synthesis Examples to be described later.
<유기 전계 발광 소자>≪ Organic electroluminescent device &
한편, 본 발명의 다른 측면은 상기한 본 발명에 따른 화학식 1로 표시되는 화합물을 포함하는 유기 전계 발광 소자(유기 EL 소자)에 관한 것이다.On the other hand, another aspect of the present invention relates to an organic electroluminescent device (organic EL device) comprising the compound represented by the formula (1) according to the present invention.
보다 구체적으로, 본 발명에 따른 유기 전계 발광 소자는 양극(anode); 음극(cathode); 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며, 상기 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함하는 것을 특징으로 한다. 이때, 상기 화학식 1로 표시되는 화합물은 1종 또는 2종 이상이 포함될 수 있다.More specifically, the organic electroluminescent device according to the present invention includes an anode; A cathode; And at least one organic material layer sandwiched between the anode and the cathode, wherein at least one of the organic material layers includes a compound represented by the formula (1). In this case, the compound represented by Formula 1 may include one kind or two or more kinds.
여기서, 본 발명의 화학식 1로 표시되는 화합물을 포함하는 유기물층은 발광층, 정공주입층, 정공수송층, 전자수송층 및 전자주입층 중 어느 하나 이상일 수 있으며, 바람직하게는 발광층, 정공수송층 및/또는 전자수송층일 수 있다.Here, the organic material layer containing the compound represented by the formula (1) of the present invention may be any one or more of a light emitting layer, a hole injecting layer, a hole transporting layer, an electron transporting layer and an electron injecting layer, Lt; / RTI >
본 발명에 따른 유기 전계 발광 소자의 발광층은 호스트 재료를 함유할 수 있는데, 이때 호스트 재료로 상기 화학식 1로 표시되는 화합물 중 어느 하나를 사용할 수 있다. 이와 같이 발광층이 상기 화학식 1로 표시되는 화합물 중 어느 하나를 함유할 경우, 발광층에서 정공과 전자의 결합력이 높아지기 때문에 효율(발광효율 및 전력효율), 수명, 휘도 및 구동전압 등이 우수한 유기 전계 발광 소자를 제공할 수 있다. 상기 화학식 1로 표시되는 화합물은 청색, 녹색 및/또는 적색의 인광 호스트, 형광 호스트, 또는 도펀트 재료로서 유기 발광 소자에 포함될 수 있다. 또한 도펀트 재료로 이용될 수 있다. The light emitting layer of the organic electroluminescent device according to the present invention may contain a host material, wherein any one of the compounds represented by Formula 1 may be used as the host material. As such, when the light emitting layer contains any one of the compounds represented by Chemical Formula 1, organic electroluminescence having excellent efficiency (light emitting efficiency and power efficiency), lifetime, luminance, driving voltage, etc., because the bonding force between holes and electrons in the light emitting layer is increased. An element can be provided. The compound represented by Formula 1 may be included in an organic light emitting device as a blue, green, and / or red phosphorescent host, a fluorescent host, or a dopant material. It can also be used as a dopant material.
본 발명의 유기 EL 소자 구조는 특별히 한정되지 않으나, 전극간에 유기물층을 1층 또는 2층 이상 적층한 구조일 수 있다. 이의 비제한적인 예를 들면 (i) 양극, 발광층, 음극; (ⅱ) 양극, 정공주입층, 정공수송층, 발광층, 전자수송층, 전자주입층, 음극; 또는 (ⅲ) 양극, 정공주입층, 정공수송층, 발광층, 음극 등의 구조를 들 수 있다.The structure of the organic EL device of the present invention is not particularly limited, but may be a structure in which one or more organic layers are laminated between electrodes. Non-limiting examples thereof include (i) an anode, a light emitting layer, a cathode; (Ii) an anode, a hole injection layer, a hole transport layer, a light emitting layer, an electron transport layer, an electron injection layer, a cathode; Or (iii) structures such as an anode, a hole injection layer, a hole transport layer, a light emitting layer, and a cathode.
또한, 본 발명에 따른 유기 EL 소자는 전술한 바와 같이 양극, 1층 이상의 유기물층 및 음극이 순차적으로 적층된 구조 뿐만 아니라, 전극과 유기물층 계면에 절연층 또는 접착층이 삽입될 수 있다. In addition, as described above, the organic EL device according to the present invention may not only have a structure in which an anode, one or more organic material layers, and a cathode are sequentially stacked, but an insulating layer or an adhesive layer may be inserted at an interface between an electrode and an organic material layer.
본 발명에 따른 유기 EL 소자에 있어서, 상기 화학식 1로 표시되는 화합물을 포함하는 유기물층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포법의 예로는 스핀 코팅, 딥코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이들에만 한정되지 않는다. In the organic EL device according to the present invention, the organic material layer containing the compound represented by Formula 1 may be formed by a vacuum deposition method or a solution coating method. Examples of the solution coating method include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.
본 발명에 따른 유기 EL 소자는 유기물층 중 1층 이상을 본 발명의 화학식 1로 표시되는 화합물을 포함하도록 형성하는 것을 제외하고는, 당 기술 분야에 알려져 있는 재료 및 방법을 이용하여 유기물층 및 전극을 형성함으로써 제조될 수 있다. The organic EL device according to the present invention forms an organic material layer and an electrode using materials and methods known in the art, except that at least one layer of the organic material layer is formed to include the compound represented by Formula 1 of the present invention. It can be manufactured by.
예컨대, 기판으로는 실리콘 웨이퍼, 석영 또는 유리판, 금속판, 플라스틱 필름이나 시트 등이 사용될 수 있다. For example, a silicon wafer, quartz or glass plate, a metal plate, a plastic film or a sheet can be used as the substrate.
양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 및 폴리아닐린과 같은 전도성 고분자; 또는 카본블랙 등이 있으나, 이들에만 한정되는 것은 아니다. Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole and polyaniline; Or carbon black, but are not limited thereto.
음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석, 또는 납과 같은 금속 또는 이들의 합금; LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있으나, 이들에만 한정되는 것은 아니다. Examples of the negative electrode material include metals such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or alloys thereof; Layer structure materials such as LiF / Al or LiO 2 / Al, but are not limited thereto.
또한, 정공 주입층, 정공 수송층 및 전자 수송층은 특별히 한정되는 것은 아니며, 당 업계에 알려진 통상의 물질이 사용될 수 있다. In addition, the hole injection layer, the hole transport layer and the electron transport layer is not particularly limited, and conventional materials known in the art may be used.
이하 본 발명을 실시예를 통하여 상세히 설명하면 다음과 같다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
[[ 합성예Synthetic example 1] 화합물 9,9'-( 1] Compound 9, 9 '- ( quinazolinequinazoline -1,3(2H,4H)-diylbis(4,1-phenylene))bis(9H-carbazole)의 합성-1,3 (2H, 4H) -diylbis (4,1-phenylene)) bis (9H-carbazole)
<단계 1> 1,2,3,4-tetrahydroquinazoline 합성<Step 1> Synthesis of 1,2,3,4-tetrahydroquinazoline
Quinazoline (10g, 76.8mmol)을 테트라하이드로퓨란 100 ㎖에 녹인 다음 NaBH4 (10g, 264mmol)을 넣고 교반하였다. 2일 동안 교반한 후 TLC를 이용하여 반응이 종결된 것을 확인한 후 증류수를 투입하고 에틸아세테이트로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(3g, 수율29%)을 얻었다. HRMS [M]+: 134.08
Quinazoline (10 g, 76.8 mmol) was dissolved in 100 mL of tetrahydrofuran, followed by addition of NaBH 4 (10 g, 264 mmol) and stirring. After stirring for 2 days, it was confirmed by TLC that the reaction was terminated, and distilled water was added thereto and extracted with ethyl acetate. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound (3 g, yield 29%). HRMS [M] < + & gt ; : 134.08
<단계 2> 9,9'-(quinazoline-1,3(2H,4H)-diylbis(4,1-phenylene))bis(9H-carbazole) 합성Synthesis of 9,9 '- (quinazoline-1,3 (2H, 4H) -diylbis (4,1-phenylene)) bis
상기 <단계 1>에서 얻은 1,2,3,4-tetrahydroquinazoline (3g, 22.3mmol)을 9-(4-bromophenyl)-9H-carbazole(15.8g, 49mmol), Pd(OAc)2(0.25g, 1.11mmol), Cs2CO3 (21.7g, 66.9mmol)과 함께 톨루엔 100ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.22g, 1.11mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. The <step 1> 1,2,3,4-tetrahydroquinazoline (3g, 22.3mmol) of 9- (4-bromophenyl) -9H- carbazole (15.8g, 49mmol) obtained from, Pd (OAc) 2 (0.25g , 1.11 mmol) and Cs 2 CO 3 (21.7 g, 66.9 mmol) were stirred in toluene (100 ml) at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.22 g, 1.11 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물 1-1 (8g, 수율58%)을 얻었다. HRMS [M]+: 616.26
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound 1-1 (8 g, yield 58%). HRMS [M] < + & gt ; : 616.26
[합성예 2] 화합물 2,2'-(quinazoline-1,3(2H,4H)-diyl)bis(9,9,10-triphenyl-9,10-dihydroacridine) 의 합성Synthesis Example 2 Synthesis of 2,2 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9,9,10-triphenyl-9,10-dihydroacridine)
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-2(수율 85%)을 얻었다. HRMS [M]+:949.19
The procedure of Synthesis Example 1 was repeated except that 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine was used in place of 9- (4-bromophenyl) -9H- -2 (yield: 85%). HRMS [M] < + & gt ; : 949.19
[합성예 3] 화합물 3,3'-(quinazoline-1,3(2H,4H)-diyl)bis(9-phenyl-9H-carbazole) 의 합성Synthesis Example 3 Synthesis of 3,3 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9-phenyl-9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9-phenyl-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-3(수율 76%)을 얻었다. HRMS [M]+:616.75
(Yield 76%) was obtained by following the same procedure as in Synthesis Example 1, except that 3-bromo-9-phenyl-9H-carbazole was used in place of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 616.75
[합성예 4] 화합물 3-(9,9'-spirobi[fluoren]-2-yl)-1-(9,9'-spirobi[fluoren]-7-yl)-1,2,3,4-tetrahydroquinazoline의 합성Synthesis Example 4 Synthesis of Compound 3- (9,9'-spirobi [fluoren] -2-yl) -1- (9,9'-spirobi [fluoren] -7- Synthesis of tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9'-spirobi[fluorene] 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-4(수율 57%)을 얻었다. HRMS [M]+:762.94
The same procedure as in Synthesis Example 1 was repeated but using 2-bromo-9,9'-spirobi [fluorene] instead of 9- (4-bromophenyl) -9H- 57%). HRMS [M] < + & gt ; : 762.94
[합성예 5] 화합물 1,3-bis(4,6-diphenylpyridin-2-yl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 5 Synthesis of Compound 1,3-bis (4,6-diphenylpyridin-2-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-5(수율 76%)을 얻었다. HRMS [M]+:592.73
(Yield 76%) was obtained by following the same procedure as in Synthesis Example 1, except that 2-bromo-4,6-diphenylpyridine was used in place of 9- (4-bromophenyl) -9H- . HRMS [M] < + & gt ; : 592.73
[합성예 6] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-2-amine의 합성Synthesis Example 6 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2- dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 4-(4-bromophenyl)dibenzo[b,d]thiophene 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-7(수율 68%)을 얻었다. HRMS [M]+:650.85
Dibenzo [b, d] thiophene instead of 4- (4-bromophenyl) -9H-carbazole was used in place of 4- (4-bromophenyl) Yield: 68%). HRMS [M] < + & gt ; : 650.85
[합성예 7] 화합물 1,3-bis(4-(dibenzo[b,d]thiophen-4-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 7 Synthesis of Compound 1,3-bis (4- (dibenzo [b, d] thiophen-4-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-9(수율 79%)을 얻었다. HRMS [M]+:720.90
The same procedure as in Synthesis Example 1 was carried out except that N- (4-bromophenyl) -N-phenylnaphthalen-1-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 79%). HRMS [M] < + & gt ; : 720.90
[합성예 8] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-1-amine 의 합성Synthesis Example 8 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2- dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-10(수율 76%)을 얻었다. HRMS [M]+:720.90
The same procedures as in Synthesis Example 1 were carried out except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 76%). HRMS [M] < + & gt ; : 720.90
[합성예 9] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,2-diyl))bis(9H-carbazole) 의 합성Synthesis Example 9 Synthesis of 9,9 '- (5,5' - (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,2-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-2-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-11(수율 80%)을 얻었다. HRMS [M]+:618.73
The same procedure as in Synthesis Example 1 was carried out except that 9- (5-bromopyridin-2-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 80%). HRMS [M] < + & gt ; : 618.73
[합성예 10] 화합물 1,3-bis(9,9-dimethyl-9H-fluoren-3-yl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 10 Synthesis of Compound 1,3-bis (9,9-dimethyl-9H-fluoren-3-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9,9-dimethyl-9H-fluorene 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-12(수율 70%)을 얻었다. HRMS [M]+:518.69
The procedure of Synthesis Example 1 was repeated except for using 3-bromo-9,9-dimethyl-9H-fluorene instead of 9- (4-bromophenyl) -9H- 70%). HRMS [M] < + & gt ; : 518.69
[합성예 11] 화합물 9,9'-(quinazoline-1,3(2H,4H)-diylbis(3,1-phenylene))bis(9H-carbazole) 의 합성Synthesis Example 11 Synthesis of 9,9 '- (quinazoline-1,3 (2H, 4H) -diylbis (3,1-phenylene)) bis (9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 9-(3-bromophenyl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-13(수율 72%)을 얻었다. HRMS [M]+:616.75
(Yield: 72%) was obtained by following the same procedure as in Synthesis Example 1, except that 9- (3-bromophenyl) -9H-carbazole was used in place of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 616.75
[합성예 12] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,3-diyl))bis(9H-carbazole) 의 합성Synthesis Example 12 Synthesis of 9,9 '- (5,5' - (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,3-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-3-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-14(수율 65%)을 얻었다. HRMS [M]+:618.73
The same procedures as in Synthesis Example 1 were carried out except that 9- (5-bromopyridin-3-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 65%). HRMS [M] < + & gt ; : 618.73
[합성예 13] 화합물 1,3-bis(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 13 Synthesis of Compound 1,3-bis (3- (imidazo [1,2-a] pyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)imidazo[1,2-a]pyridine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-15(수율 75%)을 얻었다. HRMS [M]+:518.61
The same procedure as in Synthesis Example 1 was carried out except that 2- (3-bromophenyl) imidazo [1,2-a] pyridine was used in place of 9- (4-bromophenyl) -9H- 15 (yield: 75%). HRMS [M] < + & gt ; : 518.61
[합성예 14] 화합물 1,3-bis(3-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 14 Synthesis of Compound 1,3-bis (3- (1-phenyl- 1H-benzo [d] imidazol-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-1-phenyl-1H-benzo[d]imidazole 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-16(수율 88%)을 얻었다. HRMS [M]+:670.80
The same procedure as in Synthesis Example 1 was carried out except that 2- (3-bromophenyl) -1-phenyl-1H-benzo [d] imidazole was used in place of 9- (4-bromophenyl) Compound 1-16 (yield 88%) was obtained. HRMS [M] < + & gt ; : 670.80
[합성예 15] 화합물 1,3-bis(4-(4,6-diphenylpyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 15 Synthesis of Compound 1,3-bis (4- (4,6-diphenylpyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(4-bromophenyl)-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물1-18(수율 74%)을 얻었다. HRMS [M]+:744.92
The procedure of Synthesis Example 1 was repeated except for using 2- (4-bromophenyl) -4,6-diphenylpyridine instead of 9- (4-bromophenyl) -9H-carbazole to obtain the title compound 1-18 74%). HRMS [M] < + & gt ; : 744.92
[합성예 16] N-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)-9H-fluoren-2-amine의 합성Synthesis Example 16 Synthesis of N - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl- 1,2-dihydroquinazolin-3 (4H) -yl) phenyl) -9H-fluoren-2-
<단계 1> 1,2,3,4-tetrahydroquinazoline 합성<Step 1> Synthesis of 1,2,3,4-tetrahydroquinazoline
Quinazoline (10g, 76.8mmol)을 테트라하이드로퓨란 100 ㎖에 녹인 다음 NaBH4 (10g, 264mmol)을 넣고 교반하였다. 2일동안 교반한후 TLC를 이용하여 반응이 종결된 것을 확인한 후 증류수를 투입하고 에틸아세테이트로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(3g, 수율29%)을 얻었다. HRMS [M]+: 134.08
Quinazoline (10 g, 76.8 mmol) was dissolved in 100 mL of tetrahydrofuran, followed by addition of NaBH 4 (10 g, 264 mmol) and stirring. After stirring for 2 days, it was confirmed by TLC that the reaction was terminated, and distilled water was added thereto and extracted with ethyl acetate. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound (3 g, yield 29%). HRMS [M] < + & gt ; : 134.08
<단계 2> 3-(3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole의 합성<Step 2> Synthesis of 3- (3,4-dihydroquinazolin-1 (2H) -yl) -9-phenyl-9H-carbazole
상기 <단계 1>에서 얻은 1,2,3,4-tetrahydroquinazoline (3g, 22.3mmol)을 3-bromo-9-phenyl-9H-carbazole(10.7g, 33.45mmol), Pd(OAc)2(0.25g, 1.11mol), Cs2CO3 (14.53g, 44.6mmol)과 함께 톨루엔 100ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.22g, 1.11mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. The <step 1> 1,2,3,4-tetrahydroquinazoline (3g, 22.3mmol) of 3-bromo-9-phenyl- 9H-carbazole (10.7g, 33.45mmol) obtained from, Pd (OAc) 2 (0.25g , 1.11 mol) and Cs 2 CO 3 (14.53 g, 44.6 mmol) in 100 ml of toluene, and the mixture was stirred at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.22 g, 1.11 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(3.2g, 수율38%)을 얻었다. HRMS [M]+: 375.17
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound (3.2 g, yield 38%). HRMS [M] < + & gt ; : 375.17
<단계 3> N-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)-9H-fluoren-2-amine의 합성Step 3: Synthesis of N - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl- , 2-dihydroquinazolin-3 (4H) -yl) phenyl) -9H-fluoren-2-
상기 <단계 2>에서 얻은 3-(3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole (3.2g, 8.52mmol)을 N-([1,1'-biphenyl]-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(4.4g, 8.52mmol), Pd(OAc)2(0.09g, 0.426mmol), Cs2CO3 (5.55g, 17.04mmol)과 함께 톨루엔 100ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.08g, 0.426mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. 9- phenyl-9H-carbazole (3.2 g, 8.52 mmol) obtained in the above Step 2 was dissolved in N - ([1,1'-biphenyl] (4-bromophenyl) -9,9-dimethyl-9H-fluoren-2-amine (4.4 g, 8.52 mmol), Pd (OAc) 2 (0.09 g, 0.426 mmol), Cs 2 CO 3 (5.55 g, 17.04 mmol) in 100 ml of toluene was stirred at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.08 g, 0.426 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물 1-17 (4g, 수율56%)을 얻었다. HRMS [M]+: 810.37
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound 1-17 (4 g, yield 56%). HRMS [M] < + & gt ; : 810.37
[합성예 17] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 17 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 16과 동일한 과정을 수행하여 표제 화합물1-6(수율 66%)을 얻었다. HRMS [M]+:668.83
The same procedures as in Synthesis Example 16 were carried out except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 66%). HRMS [M] < + & gt ; : 668.83
[합성예 18] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 18 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 16과 동일한 과정을 수행하여 표제 화합물1-8(수율 56%)을 얻었다. HRMS [M]+:668.83
Following the same procedure as in Synthesis Example 16, except for using N- (4-bromophenyl) -N-phenylnaphthalen-1-amine instead of 9- (4-bromophenyl) -9H- (Yield: 56%). HRMS [M] < + & gt ; : 668.83
[합성예 19] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 19 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-chloro-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 16과 동일한 과정을 수행하여 표제 화합물1-19(수율 63%)을 얻었다. HRMS [M]+:606.72
The same procedures as in Synthesis Example 16 were carried out except that 2-chloro-4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- -19 (yield: 63%). HRMS [M] < + & gt ; : 606.72
[합성예 20] 화합물 3-(3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)phenyl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 20 Synthesis of Compound 3- 3- (4,6-diphenyl-1,3,5-triazin-2-yl) phenyl) -3,4-dihydroquinazolin-1 (2H) Synthesis of 9-phenyl-9H-carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 16과 동일한 과정을 수행하여 표제 화합물1-20(수율 56%)을 얻었다. HRMS [M]+:682.81
The same procedure as in Synthesis Example 16 was carried out except that 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- To obtain the title compound 1-20 (yield: 56%). HRMS [M] < + & gt ; : 682.81
[합성예 21] 화합물 9,9'-(pyrimido[4,5-d]pyrimidine-1,3(2H,4H)-diylbis(4,1-phenylene))bis(9H-carbazole)의 합성Synthesis Example 21 Synthesis of 9,9 '- (pyrimido [4,5-d] pyrimidine-1,3 (2H, 4H) -diylbis (4,1-phenylene)
Quinoxaline 대신 pyrimido[4,5-d]pyrimidine을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 표제 화합물 2-1 (수율 30%)을 합성하였다. HRMS [M]+: 618.25
The title compound 2-1 (yield 30%) was synthesized by following the procedure of Synthesis Example 1, except that pyrimido [4,5-d] pyrimidine was used instead of quinoxaline. HRMS [M] < + & gt ; : 618.25
[합성예 22] 화합물 2,2'-(quinazoline-1,3(2H,4H)-diyl)bis(9,9,10-triphenyl-9,10-dihydroacridine) 의 합성Synthesis Example 22 Synthesis of 2,2 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9,9,10-triphenyl-9,10-dihydroacridine)
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-2(수율 70%)을 얻었다. HRMS [M]+:951.16
The same procedures as in Synthesis Example 21 were carried out except that 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine was used in place of 9- (4-bromophenyl) -9H- -2 (70% yield). HRMS [M] < + & gt ; : 951.16
[합성예 23] 화합물 3,3'-(quinazoline-1,3(2H,4H)-diyl)bis(9-phenyl-9H-carbazole) 의 합성Synthesis Example 23 Synthesis of 3,3 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9-phenyl-9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9-phenyl-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예21과 동일한 과정을 수행하여 표제 화합물2-3(수율 80%)을 얻었다. HRMS [M]+:618.73
(Yield: 80%) was obtained by following the same procedure as in Synthesis Example 21, except that 3-bromo-9-phenyl-9H-carbazole was used in place of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 618.73
[합성예 24] 화합물 3-(9,9'-spirobi[fluoren]-2-yl)-1-(9,9'-spirobi[fluoren]-7-yl)-1,2,3,4-tetrahydroquinazoline의 합성Synthesis Example 24 Synthesis of Compound 3- (9,9'-spirobi [fluoren] -2-yl) -1- (9,9'-spirobi [fluoren] -7- Synthesis of tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9'-spirobi[fluorene] 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물 2-4(수율 68%)을 얻었다. HRMS [M]+:764.91
The same procedure as in Synthesis Example 21 was repeated but using 2-bromo-9,9'-spirobi [fluorene] instead of 9- (4-bromophenyl) -9H- 68%). HRMS [M] < + & gt ; : 764.91
[합성예 25] 화합물 1,3-bis(4,6-diphenylpyridin-2-yl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 25 Synthesis of Compound 1,3-bis (4,6-diphenylpyridin-2-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물 2-5(수율 78%)을 얻었다. HRMS [M]+:594.71
(Yield 78%) was obtained by following the same procedure as in Synthesis Example 21, except that 2-bromo-4,6-diphenylpyridine was used in place of 9- (4-bromophenyl) -9H- . HRMS [M] < + & gt ; : 594.71
[합성예 26] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-2-amine의 합성Synthesis Example 26 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2-dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 4-(4-bromophenyl)dibenzo[b,d]thiophene 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-7(수율 80%)을 얻었다. HRMS [M]+:652.83
Following the same procedure as in Synthesis Example 21, except for using 4- (4-bromophenyl) dibenzo [b, d] thiophene instead of 9- (4-bromophenyl) -9H- Yield: 80%). HRMS [M] < + & gt ; : 652.83
[합성예 27] 화합물 1,3-bis(4-(dibenzo[b,d]thiophen-4-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 27 Synthesis of Compound 1,3-bis (4- (dibenzo [b, d] thiophen-4-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-9(수율 79%)을 얻었다. HRMS [M]+:722.88
The same procedures as in Synthesis Example 21 were carried out except that N- (4-bromophenyl) -N-phenylnaphthalen-1-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 79%). HRMS [M] < + & gt ; : 722.88
[합성예 28] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-1-amine 의 합성Synthesis Example 28 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2- dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-10(수율 36%)을 얻었다. HRMS [M]+:722.88
The same procedures as in Synthesis Example 21 were carried out except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 36%). HRMS [M] < + & gt ; : 722.88
[합성예 29] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,2-diyl))bis(9H-carbazole) 의 합성Synthesis Example 29 Synthesis of 9,9 '- (5,5' - (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,2-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-2-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물 2-11(수율 50%)을 얻었다. HRMS [M]+:620.70
The same procedures as in Synthesis Example 21 were carried out except that 9- (5-bromopyridin-2-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 50%). HRMS [M] < + & gt ; : 620.70
[합성예 30] 화합물 1,3-bis(9,9-dimethyl-9H-fluoren-3-yl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 30 Synthesis of Compound 1,3-bis (9,9-dimethyl-9H-fluoren-3-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9,9-dimethyl-9H-fluorene 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-12(수율 65%)을 얻었다. HRMS [M]+:520.67
The same procedures as in Synthesis Example 21 were carried out except that 3-bromo-9,9-dimethyl-9H-fluorene was used in place of 9- (4-bromophenyl) -9H- 65%). HRMS [M] < + & gt ; : 520.67
[합성예 31] 화합물 9,9'-(quinazoline-1,3(2H,4H)-diylbis(3,1-phenylene))bis(9H-carbazole) 의 합성Synthesis Example 31 Synthesis of 9,9 '- (quinazoline-1,3 (2H, 4H) -diylbis (3,1-phenylene)) bis (9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 9-(3-bromophenyl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물 2-13(수율 60%)을 얻었다. HRMS [M]+:618.73
The title compound 2-13 (yield 60%) was obtained by following the same procedure as in Synthesis Example 21, except using 9- (3-bromophenyl) -9H-carbazole instead of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 618.73
[합성예 32] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,3-diyl))bis(9H-carbazole) 의 합성Synthesis Example 32 Synthesis of 9,9 '- (5,5' - (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,3-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-3-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-14(수율 70%)을 얻었다. HRMS [M]+:620.70
The same procedures as in Synthesis Example 21 were carried out except that 9- (5-bromopyridin-3-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 70%). HRMS [M] < + & gt ; : 620.70
[합성예 33] 화합물 1,3-bis(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 33 Synthesis of Compound 1,3-bis (3- (imidazo [1,2-a] pyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)imidazo[1,2-a]pyridine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물 2-15(수율 71%)을 얻었다. HRMS [M]+:520.59
The procedure of Synthetic Example 21 was repeated except for using 2- (3-bromophenyl) imidazo [1,2-a] pyridine instead of 9- (4-bromophenyl) -9H- 15 (yield: 71%). HRMS [M] < + & gt ; : 520.59
[합성예 34] 화합물 1,3-bis(3-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 34 Synthesis of Compound 1,3-bis (3- (1-phenyl- 1H-benzo [d] imidazol-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-1-phenyl-1H-benzo[d]imidazole 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-16(수율 78%)을 얻었다. HRMS [M]+:672.78
The procedure of Synthesis Example 21 was repeated except that 2- (3-bromophenyl) -1-phenyl-1H-benzo [d] imidazole was used in place of 9- (4-bromophenyl) Compound 2-16 (yield: 78%) was obtained. HRMS [M] < + & gt ; : 672.78
[합성예 35] 화합물 1,3-bis(4-(4,6-diphenylpyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 35 Synthesis of Compound 1,3-bis (4- (4,6-diphenylpyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(4-bromophenyl)-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 21과 동일한 과정을 수행하여 표제 화합물2-18(수율 55%)을 얻었다. HRMS [M]+:746.90
Following the same procedure as in Synthesis Example 21, except for using 2- (4-bromophenyl) -4,6-diphenylpyridine instead of 9- (4-bromophenyl) -9H- 55%). HRMS [M] < + & gt ; : 746.90
[[ 합성예Synthetic example 36] 화합물 N-([1,1'- 36] Compound N - ([1,1'- biphenylbiphenyl ]-4-]-4- ylyl )-9,9-) -9,9- dimethyldimethyl -N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)- yl)phenyl)-9H-fluoren-2-amine의 합성Yl) -1,2-dihydropyrimido [4,5-d] pyrimidin-3 (4H) -yl) phenyl) -9H-fluorene -2-amine
Quinoxaline 대신 pyrimido[4,5-d]pyrimidine을 사용하는 것을 제외하고는, 상기 합성예 16과 동일한 과정을 수행하여 표제 화합물 2-17 (수율 12%)을 합성하였다. HRMS [M]+: 812.36
The title compound 2-17 (yield 12%) was synthesized by following the procedure of Synthesis Example 16, except that pyrimido [4,5-d] pyrimidine was used instead of quinoxaline. HRMS [M] < + & gt ; : 812.36
[합성예 37] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 37 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 36과 동일한 과정을 수행하여 표제 화합물 2-6(수율 50%)을 얻었다. HRMS [M]+:670.80
The same procedures as in Synthesis Example 36 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 50%). HRMS [M] < + & gt ; : 670.80
[합성예 38] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 38 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 36과 동일한 과정을 수행하여 표제 화합물 2-8(수율 68%)을 얻었다. HRMS [M]+:670.80
The same procedures as in Synthesis Example 36 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-1-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 68%). HRMS [M] < + & gt ; : 670.80
[합성예 39] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 39 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-chloro-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 36과 동일한 과정을 수행하여 표제 화합물 2-19(수율 74%)을 얻었다. HRMS [M]+:608.69
The same procedures as in Synthesis Example 36 were carried out except that 2-chloro-4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- -19 (yield: 74%). HRMS [M] < + & gt ; : 608.69
[합성예 40] 화합물 3-(3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)phenyl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 40 Synthesis of Compound 3- (4- (3- (4,6-diphenyl-1,3,5-triazin-2-yl) phenyl) -3,4- dihydroquinazolin- Synthesis of 9-phenyl-9H-carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 36과 동일한 과정을 수행하여 표제 화합물 2-20(수율 70%)을 얻었다. HRMS [M]+:684.79
The same procedure as in Synthesis Example 36 was carried out except that 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- To obtain the title compound 2-20 (yield: 70%). HRMS [M] < + & gt ; : 684.79
[합성예 41] 화합물 9,9'-((4-phenylquinazoline-1,3(2H,4H)-diyl)bis(4,1-phenylene))bis(9H-carbazole)의 합성Synthesis Example 41 Synthesis of 9,9 '- ((4-phenylquinazoline-1,3 (2H, 4H) -diyl) bis (4,1-phenylene)) bis
<단계 1> 4-<Step 1> 4- phenylphenyl -1,2,3,4--1,2,3,4- tetrahydroquinazolinetetrahydroquinazoline 합성 synthesis
(Z)-(2-aminophenyl)(phenyl)methanone oxime (10g, 47.1mmol)을 에탄올 100 ㎖에 녹인 다음 Paraformaldehyde 10g을 넣고 교반한다. 수산화 암모늄 3ml를 천천히 15분간 적가한 후 온도를 서서히 올린다. 4시간 동안 환류교반한 후 TLC를 이용하여 반응이 종결된 것을 확인한 후 증류수를 투입하고 에틸아세테이트로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(8.1g, 수율82%)을 얻었다. HRMS [M]+: 210.12
(Z) - (2-aminophenyl) (phenyl) methanone oxime (10 g, 47.1 mmol) was dissolved in ethanol (100 mL), followed by addition of 10 g of paraformaldehyde . 3 ml of ammonium hydroxide is slowly added dropwise over 15 minutes, then the temperature is gradually increased. After refluxing for 4 hours, the reaction was terminated by TLC. Distilled water was added and extracted with ethyl acetate. The organic layer is dried over Na 2 SO 4 and purified by distillation under a reduced pressure and then purified by column chromatography to give the title compound (8.1g, 82% yield). HRMS [M] < + & gt ; : 210.12
<단계 2> 9-phenyl-3-(4-phenyl-3,4-dihydroquinazolin-1(2H)-yl)-9H-carbazole합성Step 2 Synthesis of 9-phenyl-3- (4-phenyl-3,4-dihydroquinazolin-1 (2H) -yl) -9H-carbazole
상기 <단계 1>에서 얻은 4-phenyl-1,2,3,4-tetrahydroquinazoline (8g, 38mmol)을 9-(4-bromophenyl)-9H-carbazole(25.7g, 79.8mmol), Pd(OAc)2(0.42g, 1.9mmol), Cs2CO3 (37g, 114mmol)과 함께 톨루엔 150ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.38g, 1.9mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. The <step 1> 4-phenyl-1,2,3,4- tetrahydroquinazoline (8g, 38mmol) of 9- (4-bromophenyl) -9H- carbazole (25.7g, 79.8mmol) obtained from, Pd (OAc) 2 (0.42 g, 1.9 mmol) and Cs 2 CO 3 (37 g, 114 mmol) in 150 ml of toluene at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.38 g, 1.9 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물 3-1 (18.42g, 수율70%)을 얻었다. HRMS [M]+: 692.29
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to give the title compound 3-1 (18.42 g, yield 70%). HRMS [M] < + & gt ; : 692.29
[합성예 42] 화합물 2,2'-(quinazoline-1,3(2H,4H)-diyl)bis(9,9,10-triphenyl-9,10-dihydroacridine) 의 합성Synthesis Example 42 Synthesis of 2,2 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9,9,10-triphenyl-9,10-dihydroacridine)
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-2(수율 58%)을 얻었다. HRMS [M]+:1025.28
The same procedures as in Synthesis Example 41 were carried out except that 2-bromo-9,9,10-triphenyl-9,10-dihydroacridine was used in place of 9- (4-bromophenyl) -9H- -2 (yield: 58%). HRMS [M] < + & gt ; : 1025.28
[합성예 43] 화합물 3,3'-(quinazoline-1,3(2H,4H)-diyl)bis(9-phenyl-9H-carbazole) 의 합성Synthesis Example 43 Synthesis of 3,3 '- (quinazoline-1,3 (2H, 4H) -diyl) bis (9-phenyl-9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9-phenyl-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-3(수율 60%)을 얻었다. HRMS [M]+:692.85
The title compound 3-3 (yield 60%) was obtained by following the same procedure as in Synthesis 41, but using 3-bromo-9-phenyl-9H-carbazole instead of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 692.85
[합성예 44] 화합물 3-(9,9'-spirobi[fluoren]-2-yl)-1-(9,9'-spirobi[fluoren]-7-yl)-1,2,3,4-tetrahydroquinazoline의 합성Synthesis Example 44 Synthesis of Compound 3- (9,9'-spirobi [fluoren] -2-yl) -1- (9,9'-spirobi [fluoren] -7- Synthesis of tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-9,9'-spirobi[fluorene] 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-4(수율 62%)을 얻었다. HRMS [M]+:839.03
The same procedure as in Synthesis Example 41 was repeated but using 2-bromo-9,9'-spirobi [fluorene] instead of 9- (4-bromophenyl) -9H- 62%). HRMS [M] < + & gt ; : 839.03
[합성예 45] 화합물 1,3-bis(4,6-diphenylpyridin-2-yl)-1,2,3,4-tetrahydroquinazoline 의 합성[Synthesis Example 45] Synthesis of 1,3-bis (4,6-diphenylpyridin-2-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-bromo-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-5(수율 68%)을 얻었다. HRMS [M]+:668.83
(Yield 68%) was obtained by following the same procedure as in Synthesis Example 41, except that 2-bromo-4,6-diphenylpyridine was used in place of 9- (4-bromophenyl) -9H- . HRMS [M] < + & gt ; : 668.83
[합성예 46] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-2-amine의 합성Synthesis Example 46 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2-dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 4-(4-bromophenyl)dibenzo[b,d]thiophene 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-7(수율 70%)을 얻었다. HRMS [M]+:726.95
Dibenzo [b, d] thiophene instead of 4- (4-bromophenyl) -9H-carbazole was used in place of 4- (4-bromophenyl) Yield: 70%). HRMS [M] < + & gt ; : 726.95
[합성예 47] 화합물 1,3-bis(4-(dibenzo[b,d]thiophen-4-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 47 Synthesis of Compound 1,3-bis (4- (dibenzo [b, d] thiophen-4-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-9(수율 71%)을 얻었다. HRMS [M]+:797.00
The same procedures as in Synthesis Example 41 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-1-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 71%). HRMS [M] < + >: 797.00
[합성예 48] 화합물 N-phenyl-N-(4-(1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)naphthalen-1-amine 의 합성Synthesis Example 48 Synthesis of Compound N-phenyl-N- (4- (1- (9-phenyl-9H-carbazol-3-yl) -1,2- dihydroquinazolin- Synthesis of -amine
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-10(수율 66%)을 얻었다. HRMS [M]+:797.00
The same procedures as in Synthesis Example 41 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 66%). HRMS [M] < + >: 797.00
[합성예 49] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,2-diyl))bis(9H-carbazole) 의 합성Synthesis Example 49 Synthesis of 9,9 '- (5,5'- (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,2-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-2-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-11(수율 60%)을 얻었다. HRMS [M]+:694.82
The same procedures as in Synthesis Example 41 were carried out except that 9- (5-bromopyridin-2-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 60%). HRMS [M] < + & gt ; : 694.82
[합성예 50] 화합물 1,3-bis(9,9-dimethyl-9H-fluoren-3-yl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 50 Synthesis of 1,3-bis (9,9-dimethyl-9H-fluoren-3-yl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 3-bromo-9,9-dimethyl-9H-fluorene 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-12(수율 52%)을 얻었다. HRMS [M]+:594.79
The same procedure as in Synthesis Example 41 was repeated but using 3-bromo-9,9-dimethyl-9H-fluorene instead of 9- (4-bromophenyl) -9H- 52%). HRMS [M] < + & gt ; : 594.79
[합성예 51] 화합물 9,9'-(quinazoline-1,3(2H,4H)-diylbis(3,1-phenylene))bis(9H-carbazole) 의 합성Synthesis Example 51 Synthesis of 9,9 '- (quinazoline-1,3 (2H, 4H) -diylbis (3,1-phenylene)) bis (9H-carbazole)
9-(4-bromophenyl)-9H-carbazole 대신 9-(3-bromophenyl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-13(수율 54%)을 얻었다. HRMS [M]+:692.85
The title compound 3-13 (yield 54%) was prepared using the same procedure as in Synthesis 41, except that 9- (3-bromophenyl) -9H-carbazole was used in place of 9- (4-bromophenyl) ). HRMS [M] < + & gt ; : 692.85
[합성예 52] 화합물 9,9'-(5,5'-(quinazoline-1,3(2H,4H)-diyl)bis(pyridine-5,3-diyl))bis(9H-carbazole) 의 합성Synthesis Example 52 Synthesis of 9,9 '- (5,5' - (quinazoline-1,3 (2H, 4H) -diyl) bis (pyridine-5,3-diyl)) bis (9H-
9-(4-bromophenyl)-9H-carbazole 대신 9-(5-bromopyridin-3-yl)-9H-carbazole 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-14(수율 64%)을 얻었다. HRMS [M]+:694.82
The same procedures as in Synthesis Example 41 were carried out except that 9- (5-bromopyridin-3-yl) -9H-carbazole was used in place of 9- (4-bromophenyl) -9H- (Yield: 64%). HRMS [M] < + & gt ; : 694.82
[합성예 53] 화합물 1,3-bis(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 53 Synthesis of 1,3-bis (3- (imidazo [1,2-a] pyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)imidazo[1,2-a]pyridine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-15(수율 70%)을 얻었다. HRMS [M]+:594.71
The same procedure as in Synthesis Example 41 was performed, except that 2- (3-bromophenyl) imidazo [1,2-a] pyridine was used in place of 9- (4-bromophenyl) -9H- 15 (yield: 70%). HRMS [M] < + & gt ; : 594.71
[합성예 54] 화합물 1,3-bis(3-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 54 Synthesis of 1,3-bis (3- (1-phenyl-1H-benzo [d] imidazol-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-1-phenyl-1H-benzo[d]imidazole 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-16(수율 65%)을 얻었다. HRMS [M]+:746.90
The same procedure as in Synthesis Example 41 was carried out except that 2- (3-bromophenyl) -1-phenyl-1H-benzo [d] imidazole was used in place of 9- (4-bromophenyl) Compound 3-16 (yield: 65%) was obtained. HRMS [M] < + & gt ; : 746.90
[합성예 55] 화합물 1,3-bis(4-(4,6-diphenylpyridin-2-yl)phenyl)-1,2,3,4-tetrahydroquinazoline 의 합성Synthesis Example 55 Synthesis of 1,3-bis (4- (4,6-diphenylpyridin-2-yl) phenyl) -1,2,3,4-tetrahydroquinazoline
9-(4-bromophenyl)-9H-carbazole 대신 2-(4-bromophenyl)-4,6-diphenylpyridine 를 사용하는 것을 제외하고는, 상기 합성예 41과 동일한 과정을 수행하여 표제 화합물 3-18(수율 60%)을 얻었다. HRMS [M]+:821.02
The same procedure as in Synthesis Example 41 was repeated but using 2- (4-bromophenyl) -4,6-diphenylpyridine instead of 9- (4-bromophenyl) -9H- 60%). HRMS [M] < + & gt ; : 821.02
[합성예 56] 화합물 N-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-N-(4-(8-(9-phenyl-9H-carbazol-3-yl)-7,8-dihydropteridin-5(6H)-yl)phenyl)-9H-fluoren-2-amine의 합성Synthesis Example 56 Synthesis of Compound N - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl-N- (4- (8- (9- -7,8-dihydropteridin-5 (6H) -yl) phenyl) -9H-fluoren-2-amine
<단계 1> 4-phenyl-1,2,3,4-tetrahydroquinazoline 합성<Step 1> Synthesis of 4-phenyl-1,2,3,4-tetrahydroquinazoline
(Z)-(2-aminophenyl)(phenyl)methanone oxime (10g, 47.1mmol)을 에탄올 100 ㎖에 녹인 다음 Paraformaldehyde 10g을 넣고 교반한다. 수산화 암모늄 3ml를 천천히 15분간 적가한 후 온도를 서서히 올린다. 4시간 동안 환류교반한 후 TLC를 이용하여 반응이 종결된 것을 확인한 후 증류수를 투입하고 에틸아세테이트로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(8.1g, 수율82%)을 얻었다. (Z) - (2-aminophenyl) (phenyl) methanone oxime (10 g, 47.1 mmol) was dissolved in ethanol (100 mL), followed by addition of 10 g of paraformaldehyde . 3 ml of ammonium hydroxide is slowly added dropwise over 15 minutes, then the temperature is gradually increased. After refluxing for 4 hours, the reaction was terminated by TLC. Distilled water was added and extracted with ethyl acetate. The organic layer is dried over Na 2 SO 4 and purified by distillation under a reduced pressure and then purified by column chromatography to give the title compound (8.1g, 82% yield).
HRMS [M]+: 210.12
HRMS [M] < + & gt ; : 210.12
<단계 2> 9-phenyl-3-(4-phenyl-3,4-dihydroquinazolin-1(2H)-yl)-9H-carbazole의 합성Synthesis of 9-phenyl-3- (4-phenyl-3,4-dihydroquinazolin-1 (2H) -yl) -9H-carbazole
상기 <단계 1>에서 얻은 4-phenyl-1,2,3,4-tetrahydroquinazoline (8g, 38.04mmol)을 3-bromo-9-phenyl-9H-carbazole(14.7g, 45.6mmol), Pd(OAc)2(0.42g, 1.9mol), Cs2CO3 (24.7g, 76.08mmol)과 함께 톨루엔 200ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.38g, 1.9mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. 9-phenyl-9H-carbazole (14.7 g, 45.6 mmol), Pd (OAc) 4-phenyl-1,2,3,4-tetrahydroquinazoline (8 g, 38.04 mmol) 2 (0.42 g, 1.9 mol) and Cs 2 CO 3 (24.7 g, 76.08 mmol) in 200 ml of toluene at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.38 g, 1.9 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물(8.5g, 수율50%)을 얻었다. HRMS [M]+: 451.2
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound (8.5 g, yield 50%). HRMS [M] < + & gt ; : 451.2
<단계 3> N-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-N-(4-(4-phenyl-1-(9-phenyl-9H-carbazol-3-yl)-1,2-dihydroquinazolin-3(4H)-yl)phenyl)-9H-fluoren-2-amine의 합성Step 3: Synthesis of N - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl- yl) -1,2-dihydroquinazolin-3 (4H) -yl) phenyl) -9H-fluoren-
상기 <단계 2>에서 얻은 9-phenyl-3-(4-phenyl-3,4-dihydroquinazolin-1(2H)-yl)-9H-carbazole (8.5g, 18.8mmol)을 N-([1,1'-biphenyl]-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(11.66g, 22.5mmol), Pd(OAc)2(0.21g, 0.94mmol), Cs2CO3 (12.2g, 37.6mmol)과 함께 톨루엔 150ml에 녹인 상온에서 15분 동안 교반하였다. 이후, 트리-(터트-부틸)포스핀 (0.19g, 0.94mmol)을 천천히 적가한 후 반응 혼합물을 24 시간 동안 환류 교반하였다. 9-phenyl-3- (4-phenyl-3,4-dihydroquinazolin-1 (2H) -yl) -9H-carbazole (8.5 g, 18.8 mmol) obtained in the above Step 2 was dissolved in N - (11.66 g, 22.5 mmol), Pd (OAc) 2 (0.21 g, 0.94 mmol) was added to a solution of 4- ) And Cs 2 CO 3 (12.2 g, 37.6 mmol) in 150 ml of toluene, and the mixture was stirred at room temperature for 15 minutes. Thereafter, tri- (tert-butyl) phosphine (0.19 g, 0.94 mmol) was slowly added dropwise and the reaction mixture was refluxed for 24 hours.
반응이 종결된 후 증류수를 넣고 다이클로로메틸용액으로 추출하였다. 유기층을 Na2SO4 로 건조하고 감압하에 증류한 다음 컬럼 크로마토그래피로 정제하여 표제 화합물 3-17 (7.4g, 수율44.5%)을 얻었다. HRMS [M]+: 886.4
After the reaction was completed, distilled water was added and the mixture was extracted with dichloromethyl solution. The organic layer was dried over Na 2 SO 4 , distilled under reduced pressure, and then purified by column chromatography to obtain the title compound 3-17 (7.4 g, yield 44.5%). HRMS [M] < + & gt ; : 886.4
[합성예 57] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 57 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-2-amine 를 사용하는 것을 제외하고는, 상기 합성예 56과 동일한 과정을 수행하여 표제 화합물 3-6(수율 51%)을 얻었다. HRMS [M]+:744.92
The same procedures as in Synthesis Example 56 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-2-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 51%). HRMS [M] < + & gt ; : 744.92
[합성예 58] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 58 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 N-(4-bromophenyl)-N-phenylnaphthalen-1-amine 를 사용하는 것을 제외하고는, 상기 합성예 56과 동일한 과정을 수행하여 표제 화합물 3-8(수율 48%)을 얻었다. HRMS [M]+:744.92
The same procedures as in Synthesis Example 56 were carried out, except that N- (4-bromophenyl) -N-phenylnaphthalen-1-amine was used in place of 9- (4-bromophenyl) -9H- (Yield: 48%). HRMS [M] < + & gt ; : 744.92
[합성예 59] 화합물 3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 59 Synthesis of Compound 3- (4,6-diphenyl-1,3,5-triazin-2-yl) -3,4-dihydroquinazolin-1 (2H) Synthesis of -carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-chloro-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 56과 동일한 과정을 수행하여 표제 화합물 3-19(수율 56%)을 얻었다. HRMS [M]+:682.81
The same procedures as in Synthesis Example 56 were carried out except that 2-chloro-4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- -19 (yield: 56%). HRMS [M] < + & gt ; : 682.81
[합성예 60] 화합물 3-(3-(3-(4,6-diphenyl-1,3,5-triazin-2-yl)phenyl)-3,4-dihydroquinazolin-1(2H)-yl)-9-phenyl-9H-carbazole 의 합성Synthesis Example 60 Synthesis of Compound 3- (3- (4,6-diphenyl-1,3,5-triazin-2-yl) phenyl) -3,4-dihydroquinazolin-1 (2H) Synthesis of 9-phenyl-9H-carbazole
9-(4-bromophenyl)-9H-carbazole 대신 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine 를 사용하는 것을 제외하고는, 상기 합성예 56과 동일한 과정을 수행하여 표제 화합물 3-20(수율 66%)을 얻었다. HRMS [M]+:758.91
The same procedure as in Synthesis Example 56 was carried out except that 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine was used in place of 9- (4-bromophenyl) -9H- To obtain the title compound 3-20 (yield 66%). HRMS [M] < + & gt ; : 758.91
[실시예 1~21] 녹색 유기 EL 소자의 제작[Examples 1 to 21] Production of green organic EL device
앞서 합성예에서 합성된 각 화합물(1-1, 1-3, 1-4, 1-6, 1-9, 1-12, 1-13, 2-1, 2-3, 2-4, 2-6, 2-9, 2-12, 2-13, 3-1, 3-3, 3-4, 3-6, 3-9, 3-12, 3-13)을 통상적으로 알려진 방법으로 고순도 승화정제를 수행한 후 하기 과정에 따라 녹색 유기 EL 소자를 제작하였다. The compounds (1-1, 1-3, 1-4, 1-6, 1-9, 1-12, 1-13, 2-1, 2-3, 2-4, 3-, 3-, 3-, 3-, 3-, 3-, 3-, 3-, 3-, After performing the sublimation purification, a green organic EL device was fabricated according to the following procedure.
먼저, ITO (Indium tin oxide)가 1500Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후 UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음 UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, a glass substrate coated with ITO (Indium Tin Oxide) with a thickness of 1500 Å was washed with distilled water ultrasonic waves. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried and transferred to a UV OZONE cleaner (Power Sonic 405, Hoshin Tech), the substrate was cleaned using UV for 5 minutes, The substrate was transferred.
이렇게 준비된 ITO 투명 전극 위에 m-MTDATA (60 nm)/TCTA (80 nm)/ 화합물 1-1, 1-3, 1-4, 1-6, 1-9, 1-12, 1-13, 2-1, 2-3, 2-4, 2-6, 2-9, 2-12, 2-13, 3-1, 3-3, 3-4, 3-6, 3-9, 3-12, 3-13 (각각) + 10 % Ir(ppy)3 (300nm)/BCP (10 nm)/Alq3 (30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 EL 소자를 제작하였다. M-MTDATA (60 nm) / TCTA (80 nm) / Compounds 1-1, 1-3, 1-4, 1-6, 1-9, 1-12, 1-13, -1, 2-3, 2-4, 2-6, 2-9, 2-12, 2-13, 3-1, 3-3, 3-4, 3-6, 3-9, 3-12 , 3-13 (each) + 10% Ir (ppy) 3 (300 nm) / BCP (10 nm) / Alq 3 (30 nm) / LiF (1 nm) / Al Respectively.
m-MTDATA, TCTA, Ir(ppy)3, CBP 및 BCP의 구조는 하기와 같다.The structures of m-MTDATA, TCTA, Ir (ppy) 3 , CBP and BCP are as follows.
[비교예 1] 녹색 유기 EL 소자의 제작[Comparative Example 1] Production of green organic EL device
발광층 형성시 발광 호스트 물질로서 화합물 1-1 대신 CBP를 사용하는 것을 제외하고는 실시예 1과 동일한 과정으로 녹색 유기 EL 소자를 제작하였다.
A green organic EL device was fabricated in the same manner as in Example 1, except that CBP was used instead of Compound 1-1 as a luminescent host material in forming the light emitting layer.
[평가예 1][Evaluation Example 1]
실시예 1~21 및 비교예 1에서 제작한 각각의 녹색 유기 EL 소자에 대하여 전류밀도 10 mA/㎠에서의 구동전압, 전류효율 및 발광 피크를 측정하고, 그 결과를 하기 표 1에 나타내었다.The driving voltage, current efficiency and emission peak at the current density of 10 mA / cm 2 were measured for each of the green organic EL devices manufactured in Examples 1 to 21 and Comparative Example 1, and the results are shown in Table 1 below.
(V)Driving voltage
(V)
(nm)EL peak
(nm)
(cd/A)Current efficiency
(cd / A)
상기 표 1에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층으로 사용하는 실시예 1~21의 녹색 유기 EL 소자는 종래 CBP를 사용하는 비교예 1의 녹색 유기 EL 소자와 비교해 볼 때 효율 및 구동전압 면에서 보다 우수한 성능을 나타내는 것을 알 수 있다.
As shown in Table 1, the green organic EL devices of Examples 1 to 21 using the compound according to the present invention as a light emitting layer had higher efficiency and driving voltage than the green organic EL device of Comparative Example 1 using conventional CBP It can be seen that it exhibits better performance in terms of surface area.
[실시예 22~48 ] 청색 유기 EL 소자의 제조[Examples 22 to 48] Preparation of blue organic EL device
앞서 합성예에서 합성된 각 화합물 (1-5, 1-11, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 2-5, 2-11, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 3-5, 3-11, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20) 을 통상적으로 알려진 방법으로 고순도 승화정제를 수행한 후 아래의 과정에 따라 청색 유기 EL 소자를 제작하였다.The compounds (1-5, 1-11, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 2-5, 2 -11, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 3-5, 3-11, 3-14, 3-15, 3-16 , 3-17, 3-18, 3-19, 3-20) were subjected to high purity sublimation purification by a conventionally known method, and blue organic EL devices were fabricated according to the following procedure.
먼저, ITO (Indium tin oxide)가 1500Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후 UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음 UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, a glass substrate coated with ITO (Indium Tin Oxide) with a thickness of 1500 Å was washed with distilled water ultrasonic waves. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried and transferred to a UV OZONE cleaner (Power Sonic 405, Hoshin Tech), the substrate was cleaned using UV for 5 minutes, The substrate was transferred.
이렇게 준비된 ITO 투명 전극 위에 CuPc (10 nm)/ TPAC (30 nm)/ 화합물 1-5, 1-11, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20, 2-5, 2-11, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 3-5, 3-11, 3-14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20 (각각) + 7 % Flrpic (30nm)/ Alq3 (30 nm)/ LiF (0.2 nm)/Al (150 nm) 순으로 적층하여 유기 EL 소자를 제작하였다. On this ITO transparent electrode, CuPc (10 nm) / TPAC (30 nm) / Compounds 1-5, 1-11, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19 , 1-20, 2-5, 2-11, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 3-5, 3-11, 3 (30 nm) / Alq 3 (30 nm) / LiF (0.2 nm) / 7, respectively) + 14, 3-15, 3-16, 3-17, 3-18, 3-19, 3-20 Al (150 nm) were stacked in this order to fabricate an organic EL device.
CuPc, TPAC, Flrpic의 구조는 하기와 같다.The structures of CuPc, TPAC, and Flrpic are as follows.
[비교예 2] 유기 EL 소자의 제작Comparative Example 2 Fabrication of Organic EL Device
발광층 형성시 발광 호스트 물질로서 화합물 1-5 대신 CBP를 사용하는 것을 제외하고는 실시예 22와 동일한 과정으로 청색 유기 EL 소자를 제작하였다.
A blue organic EL device was fabricated in the same manner as in Example 22, except that CBP was used instead of Compound 1-5 as a luminescent host material in forming the light emitting layer.
[평가예 2][Evaluation Example 2]
실시예 22~ 48 및 비교예 2에서 제작한 각각의 청색 유기 EL 소자에 대하여 전류밀도 10 mA/㎠에서의 구동전압, 전류효율 및 발광 피크를 측정하고, 그 결과를 하기 표 2에 나타내었다.The driving voltage, current efficiency and emission peak at current densities of 10 mA / cm 2 were measured for each of the blue organic EL devices manufactured in Examples 22 to 48 and Comparative Example 2, and the results are shown in Table 2 below.
(V)Driving voltage
(V)
(nm)EL peak
(nm)
(cd/A)Current efficiency
(cd / A)
상기 표 2에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층으로 사용하는 실시예 22~48의 청색 유기 EL 소자는 종래 CBP를 사용하는 비교예 2의 청색 유기 EL 소자와 비교해 볼 때 효율 및 구동전압 면에서 보다 우수한 성능을 나타내는 것을 알 수 있다.As shown in Table 2, the blue organic EL devices of Examples 22 to 48 using the compound according to the present invention as a light emitting layer had a higher efficiency and a higher driving voltage than the blue organic EL device of Comparative Example 2 using CBP It can be seen that it exhibits better performance in terms of surface area.
Claims (8)
[화학식 1]
상기 식에서,
X 및 Y는 서로 같거나 또는 상이하며, 각각 독립적으로 N 또는 CH이고;
R1 및 R2은 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, -NR3R4, 치환 또는 비치환된 C3~C40의 시클로알킬기, 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며,
여기서 R3 및 R4는 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며,
R5는 H, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, -NRaRb, 치환 또는 비치환된 C3~C40의 시클로알킬기 및 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기로 이루어진 군에서 선택되거나, 또는 이들이 인접하는 기와 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성하는 기이며,
여기서 Ra, Rb는 서로 같거나 또는 상이하며, 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기 및 치환 또는 비치환된 C3~C40의 시클로알킬기로 이루어진 군에서 선택되며, 또는 이들이 인접하는 기들은 서로 결합하여 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리 또는 축합 헤테로방향족 고리를 형성할 수 있으며,
상기 C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C3~C40의 시클로알킬기 및 핵원자수 3 내지 40의 헤테로시클로알킬기는, 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C6~C40의 아릴알킬기, C3~C40의 시클로알킬기, C3~C40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되는 하나 이상의 치환기로 치환될 수 있다.A compound represented by the following formula (1):
[Chemical Formula 1]
In this formula,
X and Y are the same or different and are each independently N or CH;
R 1 and R 2 are the same or different and each independently represents a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 ~ C 40 of the alkynyl group, a substituted or unsubstituted C 6 ~ C 40 aryl group, a substituted or unsubstituted nuclear atoms of 5 to 40 heteroaryl group, a substituted or unsubstituted C 6 ~ aryloxy of C 40 A substituted or unsubstituted C 1 to C 40 alkyloxy group, -NR 3 R 4 , a substituted or unsubstituted C 3 to C 40 cycloalkyl group, and a substituted or unsubstituted 3 to 40 Or a group which forms a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring with a group adjacent to the condensed aliphatic ring, condensed aromatic ring, condensed heteroaromatic ring or condensed heteroaromatic ring,
Wherein R 3 and R 4 are the same as or different from each other, and each independently a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted nucleus atoms of 5 to 40 heteroaryl group, a substituted or unsubstituted C 3 ~ C 40 cycloalkyl group, and a substituted or unsubstituted selected from the group consisting of a heterocycloalkyl group of the number of ring nucleus atoms of 3 to 40, or, or they are adjacent And a group forming a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring with
R 5 is H, a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group, a C 6 ~ C 40 aryl group, a substituted or unsubstituted nuclear atoms heteroaryl of 5 to 40, a substituted or unsubstituted C 6 ~ C 40 of the aryloxy group, a substituted or unsubstituted C 1 ~ C 40 alkyloxy of, -NR a R b, a substituted or unsubstituted selected from the group consisting of a cycloalkyl group of C 3 ~ C 40 unsubstituted and substituted or unsubstituted heteroaryl number of 3 to 40 nuclear atoms or a cycloalkyl group, or they A group forming a condensed aliphatic ring, a condensed aromatic ring, a condensed hetero aliphatic ring or a condensed heteroaromatic ring,
Wherein R a and R b are the same as or different from each other, and each independently a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group, substituted or unsubstituted C 6 to C 40 aryl group, substituted or unsubstituted heteroaryl group having 5 to 40 nuclear atoms, substituted or unsubstituted C 6 to C 40 aryl An oxy group, a substituted or unsubstituted C 1 -C 40 alkyloxy group, and a substituted or unsubstituted C 3 -C 40 cycloalkyl group, or groups adjacent thereto are bonded to each other to form a condensed aliphatic ring Can form a condensed aromatic ring, a condensed heteroaliphatic ring or a condensed heteroaromatic ring,
The C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, nuclear atoms aryl of from 5 to 40 heteroaryl group, C 6 ~ The C 40 to C 40 aryloxy group, the C 1 to C 40 alkyloxy group, the C 3 to C 40 cycloalkyl group, and the heterocyclic cycloalkyl group having 3 to 40 nuclear atoms are each independently selected from the group consisting of deuterium, halogen, cyano, C 1 a ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of the An aryloxy group, a C 1 to C 40 alkyloxy group, a C 6 to C 40 arylamine group, a C 6 to C 40 arylalkyl group, a C 3 to C 40 cycloalkyl group, a C 3 to C 40 heterocyclo An alkyl group, a C 1 to C 40 alkylsilyl group, and a C 6 to C 40 arylsilyl group.
[화학식 2]
[화학식 3]
[화학식 4]
상기 식에서,
R1은 C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기 또는 NR3R4 이고;
R2, R3, 및 R4는 제1항에서 정의한 바와 같다. The compound according to claim 1, wherein the compound represented by the formula (1) is any one selected from compounds represented by the following formulas (2) to (4)
(2)
(3)
[Chemical Formula 4]
In this formula,
R 1 is a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms or NR 3 R 4 ;
R 2 , R 3 , and R 4 are as defined in claim 1.
3. The compound according to claim 2, wherein the compound represented by the formula (2) is selected from the group of compounds represented by the following formula:
3. The compound according to claim 2, wherein the compound represented by the formula (3) is selected from the group of compounds represented by the following formula:
3. The compound according to claim 2, wherein the compound represented by the formula (4) is selected from the group of compounds represented by the following formula:
상기 유기물층 중에서 적어도 하나는 제1항 내지 제6항 중 어느 한 항에 따른 화합물을 포함하는 것을 특징으로 하는 유기 전계 발광 소자. An organic electroluminescent device comprising: (i) a cathode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode,
Wherein at least one of the organic material layers comprises a compound according to any one of claims 1 to 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120092403A KR101488563B1 (en) | 2012-08-23 | 2012-08-23 | Organic light-emitting compound and organic electroluminescent device using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120092403A KR101488563B1 (en) | 2012-08-23 | 2012-08-23 | Organic light-emitting compound and organic electroluminescent device using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140026783A true KR20140026783A (en) | 2014-03-06 |
KR101488563B1 KR101488563B1 (en) | 2015-02-02 |
Family
ID=50641177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20120092403A KR101488563B1 (en) | 2012-08-23 | 2012-08-23 | Organic light-emitting compound and organic electroluminescent device using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101488563B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115700269A (en) * | 2021-07-30 | 2023-02-07 | 宁波卢米蓝新材料有限公司 | Organic electroluminescent composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3880200B2 (en) | 1997-06-25 | 2007-02-14 | 三井化学株式会社 | Organic electroluminescence device |
JP4377198B2 (en) | 2003-10-22 | 2009-12-02 | 富士フイルム株式会社 | Organic electroluminescence device |
KR100864364B1 (en) | 2005-12-13 | 2008-10-17 | 주식회사 엘지화학 | Novel imidazoquinazoline derivative, process for preparing the same, and organic electronic device using the same |
US9444059B2 (en) * | 2013-02-21 | 2016-09-13 | Semiconductor Energy Laboratory Co., Ltd. | Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device |
-
2012
- 2012-08-23 KR KR20120092403A patent/KR101488563B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115700269A (en) * | 2021-07-30 | 2023-02-07 | 宁波卢米蓝新材料有限公司 | Organic electroluminescent composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101488563B1 (en) | 2015-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101576562B1 (en) | Organic lightingemitting compound and organic electroluminescent device using the same | |
KR102703998B1 (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR20150077220A (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR101452578B1 (en) | Novel compounds and organic electro luminescence device using the same | |
KR20190004517A (en) | Organic compound and organic electroluminescent device using the same | |
KR101571592B1 (en) | Organic compound and organic electroluminescent device comprising the same | |
KR101827067B1 (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR101984786B1 (en) | Hetero-cyclic compound and organic light emitting device comprising the same | |
KR20130076223A (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR101599585B1 (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR20170016701A (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR102144164B1 (en) | Organic elecroluminescent device | |
KR20150103968A (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR101641411B1 (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR101667443B1 (en) | Organic compound and organic electroluminescent device comprising the same | |
KR101577112B1 (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR20180113784A (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR20150086084A (en) | Organic compounds and organic electro luminescence device comprising the same | |
KR101603372B1 (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR101488564B1 (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR101390616B1 (en) | Novel compounds and organic electro luminescence device using the same | |
KR101488563B1 (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR101571588B1 (en) | Organic light-emitting compound and organic electroluminescent device using the same | |
KR20210096954A (en) | Novel compound and organic light emitting device comprising the same | |
KR101784064B1 (en) | Heterocyclic compound including nitrogen and organic light emitting device using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
LAPS | Lapse due to unpaid annual fee |